1 / 6

Raymond N. DuBois, M.D., Ph.D. Executive Director

Biomarkers for Colorectal Cancer. The National Biomarker Development Alliance Forum March 25, 2013. Raymond N. DuBois, M.D., Ph.D. Executive Director. The Problem.

garry
Download Presentation

Raymond N. DuBois, M.D., Ph.D. Executive Director

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Biomarkers for Colorectal Cancer The National Biomarker Development Alliance Forum March 25, 2013 Raymond N. DuBois, M.D., Ph.D. Executive Director

  2. The Problem Worldwide about 1 million people develop colorectal cancer each year. Of these, 50% will die of systemic disease within 5 years of their diagnosis.

  3. 450 350 APC/Wnt -catenin Kras BRaf p53/ Bax PI3K/ PTEN Smad4 TGFRII Incidence Per/100,000 250 Normal Epithelium Metastatic spread Large Adenoma Small Adenoma Cancer 150 50 85+ 30- 34 35- 39 40- 44 45- 49 50- 54 55- 59 60- 64 65- 69 70- 74 75- 79 80- 84 Age

  4. Biomarkers for detection of CRC

  5. Impact of KRAS mutations on patients treated with an EGFR antagonist Median patient survival Treatment response rate Therapy KRAS mutation negative KRAS mutation positive KRAS mutation negative KRAS mutation positive Metastatic CRC 0/36 = 0% 34/78 = 44% 9 weeks (PFS) 32 weeks (PFS) Cetuximab Panitumumab 0/84 = 0% 21/124 = 17% 7 weeks (PFS) 12 weeks (PFS)

  6. Using biomarkers wisely has the potential to save health care dollars Assume there are ∼50,000 people per year with metastatic CRC in the USA. The estimated cost savings per patient in the cetuximab-only strategy is $8,040. Using KRAS testing to direct therapeutic decisions would save over $400 million per year

More Related